Clinical Trials
41 trialsA Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Genentech, Inc.
DETE-BR
West China Hospital
ADAPT-TN-IV
West German Study Group
ABCD RT
NRG Oncology
MEGA-TACT-BC3
Sun Yat-sen University
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
Fudan University
SIE-3
Rovi Pharmaceuticals Laboratories
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
Fudan University
POWER
Karolinska Institutet
OPTIMA-YOUNG
UNICANCER
PLANET
The Netherlands Cancer Institute
CRYSTAL
Franciscus Gasthuis & Vlietland (Hospital)
A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
POLARIS
Fudan University
A Study of Postoperative Regional Nodal Radiotherapy in Intermediate-risk Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer
Nanjing Chia-tai Tianqing Pharmaceutical
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
Fudan University
IARA
D'Or Institute for Research and Education
RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
Shandong Cancer Hospital and Institute
PANDORA
Gustave Roussy, Cancer Campus, Grand Paris
Cinderella
Fudan University
Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer
Health Hope Pharma
Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer
S.LAB (SOLOWAYS)
Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients
Fudan University
SENIOR
Fudan University
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
SWE-Switch
Region Örebro County
Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Alexandria University
ROLE OF FOLIC ACID IN THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY-INDUCED HOT FLASHES IN BREAST CANCER PATIENTS
Future University in Egypt
PROPOSE
European Institute of Oncology
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
SMART
Karolinska Institutet
Necessity of Post-mastectomy Radiotherapy After Neoadjuvant Chemotherapy and Mastectomy
Gangnam Severance Hospital
Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer
Fudan University
Hypo Versus Conventional Fractionation in Reconstructed-Breast Cancer Mastectomy Patients
Seoul National University Bundang Hospital
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
Sun Yat-sen University
Trastuzumab Combined With Pertuzumab for Adjuvant Treatment of Breast Cancer After Neoadjuvant Therapy
Shengjing Hospital
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Peking Union Medical College